A multicenter double-blind randomized controlled clinical study of parenteral gatifloxacin versus levofloxacin in the treatment of acute lower respiratory tract infections

Jia Miao,DeRong Liang,Cong L. Wen,Bing Bin Yang,Nan Jiang,Jianmei Lin,Li Zheng,Yongning Cai,Qi Shen,Xia Wang,Nan Xu,Zhu Luo

2004-01-01

Abstract:Objective: To evaluate the clinical efficacy and safety of domestic parenteral gatifloxacin for the treatment of acute lower respiratorytract infections. Methods: A multicenter double-blind randomized controlled clinical study was conducted comparing the efficacy and safety with levofloxacin. Both gatifloxacin and levofloxacin were administered intravenously at a dosage of 200mg twice daily for 7 to 10 days. Results: One hundred and sixty-two patients were enrolled in this study, 82 were in gatifloxacin group and 80 in levofloxacin group respectively. 80 patients were enrolled in ITT analysis and 70 patients were eligible for PP analysis in gatifloxacin group, while 75 patients were enrolled in ITT analysis and 66 patients were eligible for PP analysis in levofloxacin group. At the end of the treatment, the cure rates and effective rates were 48.57% and 81.43% in the gatifloxacin group, and 37.88% and 72.73% in the lexofloxacin group respectively. The bacterial eradication rates of the two groups were 98.36% and 98.28% respectively. After 7 days termination, the cure rates and effective rates were 66.64% and 86.92% in the gatifloxacin group, and 60.60% and 89.39% in the lexofloxacin group respectively. The bacterial eradication rates of the two groups were 98.36% and 98.28% respectively. There were no significant statistic differences between two groups. In two groups, 22.50% and 25.33% of patients' adverse reactions were observed, dominated by mild nausea, vomiting, dizzy, insomnia, local site reaction and elevated transaminases. Conclusion: Domestic parenteral gatifloxacin is effective and safe for the treatment of acute lower respiratory tract infections.